D.E. Shaw & Co Portfolio holdings
D. E. Shaw & Co., L.P., founded in 1988 by David E. Shaw, a former Columbia University computer science professor, is a New York City-based global investment management firm renowned for pioneering quantitative investing, managing over $70 billion in assets as of late 2024. Starting with $28 million from Paloma Partners and private investors, the firm employs sophisticated mathematical models and proprietary algorithms—initially developed by a team of scientists and programmers—to exploit market anomalies across public and private markets, including equities, fixed income, and alternatives. Headquartered above a Greenwich Village bookstore in its early days, it now boasts over 2,500 employees across offices in North America, Europe, and Asia, led by a seven-member Executive Committee since Shaw stepped back in 2001 to focus on D. E. Shaw Research. Despite setbacks like the 1998 Russia debt crisis and the 2008 financial downturn, the firm has maintained a reputation for analytical rigor, risk management, and innovation, balancing its computational roots with discretionary strategies.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$9.6B |
| 2 |
Amazon
AMZN
|
+$1.56B |
| 3 |
NVIDIA
NVDA
|
+$1.1B |
| 4 |
Meta Platforms (Facebook)
META
|
+$924M |
| 5 |
SpaceX
SPCX
|
+$907M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Micron Technology
MU
|
+$2.17B |
| 2 |
Broadcom
AVGO
|
+$1.53B |
| 3 |
Microsoft
MSFT
|
+$1.05B |
| 4 |
TSMC
TSM
|
+$928M |
| 5 |
Texas Instruments
TXN
|
+$904M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 33.7% |
| 2 | Technology | 18.77% |
| 3 | Financials | 8.35% |
| 4 | Healthcare | 7.91% |
| 5 | Consumer Discretionary | 7.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
2151
Option Care Health
OPCH
$4.68B
| $5.96M | ﹤0.01% |
284,168
+133,604
| +89% | +$3.11M |
2024 Q4
6 quarters
|
|
2152
Alector
ALEC
$204M
| $5.95M | ﹤0.01% |
2,959,983
-372,852
| -11% | -$799K |
2023 Q2
12 quarters
|
|
2153
Hims & Hers Health
HIMS
$6.47B
| $5.95M | ﹤0.01% |
171,530
-423,338
| -71% | -$11.4M |
2025 Q4
2 quarters
|
|
2154
PUT
AbbVie
ABBV
$505B
| $5.94M | ﹤0.01% |
+23,600
| New | +$5.08M |
2026 Q2
0 quarters
|
|
2155
Delta Air Lines
DAL
$50.5B
| $5.93M | ﹤0.01% |
63,332
-125,029
| -66% | -$9.44M |
2013 Q2
52 quarters
|
|
2156
Lakefront Biotherapeutics American Depositary Shares
LKFT
$2.07B
| $5.93M | ﹤0.01% |
197,844
-17,874
| -8% | -$507K |
2025 Q1
5 quarters
|
|
2157
Invesco WilderHill Clean Energy ETF
PBW
$283M
| $5.93M | ﹤0.01% |
151,907
+61,302
| +68% | +$2.38M |
2025 Q4
2 quarters
|
|
2158
Lifestance Health
LFST
$4.92B
| $5.91M | ﹤0.01% |
551,831
-92,321
| -14% | -$714K |
2024 Q4
6 quarters
|
|
2159
CALL
CRISPR Therapeutics
CRSP
$4.78B
| $5.9M | ﹤0.01% |
108,200
-34,500
| -24% | -$1.82M |
2019 Q4
26 quarters
|
|
2160
Bristow Group
VTOL
$1.2B
| $5.9M | ﹤0.01% |
142,698
+4,895
| +4% | +$219K |
2013 Q2
52 quarters
|
|
2161
Schwab US Large-Cap Growth ETF
SCHG
$62.3B
| $5.88M | ﹤0.01% |
+173,698
| New | +$5.76M |
2026 Q2
0 quarters
|
|
2162
Vine Hill Capital Investment Corp II
VHCP
$309M
| $5.87M | ﹤0.01% |
588,000
| – | – |
2026 Q1
1 quarter
|
|
2163
United Bankshares
UBSI
$6.63B
| $5.87M | ﹤0.01% |
128,009
+104,232
| +438% | +$4.56M |
2025 Q1
5 quarters
|
|
2164
CALL
Caesars Entertainment
CZR
$5.87B
| $5.85M | ﹤0.01% |
194,000
-13,900
| -7% | -$392K |
2024 Q1
9 quarters
|
|
2165
Regency Centers
REG
$13.5B
| $5.85M | ﹤0.01% |
73,373
-62,306
| -46% | -$4.89M |
2025 Q4
2 quarters
|
|
2166
Caleres
CAL
$447M
| $5.85M | ﹤0.01% |
472,691
-61,469
| -12% | -$798K |
2022 Q4
14 quarters
|
|
2167
ReNew
RNW
$2.51B
| $5.83M | ﹤0.01% |
932,619
+19,652
| +2% | +$111K |
2024 Q1
9 quarters
|
|
2168
Capital Group Dividend Value ETF
CGDV
$38.3B
| $5.81M | ﹤0.01% |
+117,986
| New | +$5.56M |
2026 Q2
0 quarters
|
|
2169
CSLM Digital Asset Acquisition Corp III
KOYN
$323M
| $5.8M | ﹤0.01% |
572,077
+100
| +0% | +$1.01K |
2025 Q4
2 quarters
|
|
2170
Enovix
ENVX
$612M
| $5.8M | ﹤0.01% |
955,198
+942,741
| +7,568% | +$6.25M |
2025 Q2
4 quarters
|
|
|
EMIS
2171
Emmis Acquisition Corp
EMIS
| $5.79M | ﹤0.01% |
568,400
| – | – |
2025 Q4
2 quarters
|
|
2172
iShares S&P 100 ETF
OEF
$20.2B
| $5.79M | ﹤0.01% |
+15,814
| New | +$5.66M |
2026 Q2
0 quarters
|
|
2173
NMP Acquisition Corp
NMP
$166M
| $5.78M | ﹤0.01% |
562,420
| – | – |
2025 Q3
3 quarters
|
|
2174
PUT
KB Home
KBH
$2.86B
| $5.77M | ﹤0.01% |
92,200
| – | – |
2026 Q1
1 quarter
|
|
2175
DELISTED
Open Lending Corp
LPRO
| $5.77M | ﹤0.01% |
1,855,014
+228,437
| +14% | +$467K |
2022 Q2
16 quarters
|
|
Similar funds
D.E. Shaw & Co's Q2 2026 Portfolio in Review
As of Q2 2026, D.E. Shaw & Co held 5,360 positions worth $210B, up 26% from $166B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
D.E. Shaw & Co deployed $8.31B of net new capital in Q2 2026, opening 872 new positions and adding to 1,718 existing holdings. Its largest new stake was SpaceX: 5,340,000 shares worth $912M.
By sector, the portfolio is most concentrated in Miscellaneous at 34% of assets, up from 30% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Micron Technology, an estimated $2.17B trimmed.
- D.E. Shaw & Co's largest Q2 2026 buy was SpaceX: 5,340,000 shares worth $912M.
- D.E. Shaw & Co added most to State Street SPDR S&P 500 ETF Trust in Q2 2026, an estimated $9.6B increase.
- D.E. Shaw & Co's biggest Q2 2026 reduction was Micron Technology, cutting an estimated $2.17B.
- D.E. Shaw & Co fully exited Automatic Data Processing in Q2 2026, selling an estimated $241M.
- D.E. Shaw & Co's ten largest holdings make up 15% of its $210B portfolio in Q2 2026.
- D.E. Shaw & Co opened 872 new positions and closed 527 in Q2 2026.
- D.E. Shaw & Co's portfolio value rose 26% quarter-over-quarter to $210B.
Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.